Clinical Trial Update: Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating rosiglitazone for anti-inflammatory effects in patients with Stage 4-5 chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Chronic Kidney Disease, Inflammation | Phase 2, Phase 3 | Status: WITHDRAWN